SLC27A1抗体;SLC27A1 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P11350(SLC27A1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P11350(SLC27A1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The solute carrier family 27 member 1 (SLC27A1), also known as fatty acid transport protein 1 (FATP1), is a transmembrane protein involved in long-chain fatty acid uptake and metabolism. It plays a critical role in lipid homeostasis, cellular energy regulation, and signaling pathways linked to metabolic disorders, such as obesity and diabetes. SLC27A1 antibodies are essential tools for studying its expression, localization, and function in various tissues, including adipose tissue, skeletal muscle, and the liver.

These antibodies are commonly used in techniques like Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) to detect SLC27A1 protein levels and distribution in cellular or tissue samples. Researchers utilize them to explore SLC27A1's involvement in lipid storage, insulin sensitivity, and pathological conditions like cancer, where altered fatty acid metabolism is a hallmark. Validated SLC27A1 antibodies typically target specific epitopes, such as the C-terminal or N-terminal regions, and are verified using knockout controls or siRNA-mediated silencing to ensure specificity.

Commercial SLC27A1 antibodies are available from multiple suppliers, often developed in hosts like rabbits or mice. Their applications extend to preclinical studies, aiding in the identification of therapeutic targets for metabolic syndromes or lipid-related diseases. Proper validation, including cross-reactivity checks and performance in species-specific models, is critical for reliable experimental outcomes.